Dena Hall
Optometrist · Greenville, RINPI 1689627341
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 191 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Alcon at 30.4% of the total. Among optometrist clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $26.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Johnson & Johnson Vision Care, Inc.$923
- AbbVie$622
- Oyster Point Pharma, Inc.$382
- Bausch & Lomb Americas Inc.$329
- Sun Pharmaceutical Industries Inc.$257
- plus $1K from 13 others
What the payments were for
- Food & beverage$5,088100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 43 | $1,547 |
| Johnson & Johnson Vision Care, Inc. | 30 | $923 |
| AbbVie(2 entities) | 49 | $622 |
| Oyster Point Pharma, Inc. | 19 | $382 |
| Bausch & Lomb Americas Inc. | 8 | $329 |
| Sun Pharmaceutical Industries Inc. | 9 | $257 |
| Tarsus Pharmaceuticals, Inc. | 7 | $204 |
| Biotissue Holdings Inc. | 2 | $192 |
| Dompe US, Inc. | 8 | $163 |
| Rxsight Inc | 1 | $146 |
| Novartis | 7 | $117 |
| Maculogix, Inc. | 1 | $78 |
| Glaukos Corporation | 1 | $25 |
| Sanofi | 1 | $25 |
| Kala Pharmaceuticals, Inc. | 1 | $20 |
| ABB Con-cise Optical Group LLC | 1 | $17 |
| Coopervision Inc. | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$371
- EYSUVIS$253
- Rhopressa$249
- Acuvue$230
- RXSIGHT CONTACT LENS$146
- RXSIGHT INJECTOR CARTRIDGE$146
- RXSIGHT INJECTOR HANDPIECE$146
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$146
- LIGHT ADJUSTABLE LENS (LAL)$146
- XDEMVY$142
- Precision7$135
- INFUSE$128
- DAILIES$121
- SIMBRINZA$119
- VUITY$115
- CEQUA$114
How this compares
$5,088 in reported general payments places this provider in the 95th percentile of 226 optometrist providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 84 | $97,168 |
| RocklatanNetarsudil Mesylat/Latanoprost | 63 | $31,513 |
| XdemvyLotilaner | 16 | $30,640 |
| TyrvayaVarenicline Tartrate | 11 | $13,357 |
| VyzultaLatanoprostene Bunod | 30 | $12,877 |
| LumiganBimatoprost | 23 | $11,010 |
| CequaCyclosporine | 11 | $9,553 |
| Bepotastine Besilate | 26 | $5,651 |
| Travoprost | 13 | $5,297 |
| Latanoprost | 354 | $5,111 |
| Cyclosporine | 25 | $4,939 |
| Loteprednol Etabonate | 22 | $3,316 |
| Timolol Maleate | 114 | $1,902 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 32 | $723 |
| Dorzolamide Hcl | 16 | $628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $622 | $108,178107 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $204 | $30,64016 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $382 | $13,35711 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $329 | $12,87730 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $257 | $9,55311 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $13 | $3,31622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 226 optometrist providers in Rhode Island.
Other optometrist in Greenville
- Eric HallGreenville$4K
- Noelle JohnstonGreenville$2K
- Kriti BhagatProvidence$343K
- Maria SampalisWarwick$135K
- Stephen MontaquilaWarwick$51K
- Matthew DoyleWarwick$9K
- Georgia PatsiopoulosWarwick$9K
- Paul ZerbinopoulosSouth Kingstown$9K
- Lucia DangeloProvidence$6K
- Carl CorrowProvidence$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.